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1Department of Molecular Genetics, University of Texas Southwestern Medical Center, Dallas, TexasABSTRACT Many cellular processes are sensitive to levels of cholesterol in specific membranes and show a strongly
sigmoidal dependence on membrane composition. The sigmoidal responses of the cholesterol sensors involved in these
processes could arise from several mechanisms, including positive cooperativity (protein effects) and limited cholesterol acces-
sibility (membrane effects). Here, we describe a sigmoidal response that arises primarily from membrane effects due to sharp
changes in the chemical activity of cholesterol. Our models for eukaryotic membrane-bound cholesterol sensors are soluble
bacterial toxins that show an identical switch-like specificity for endoplasmic reticulum membrane cholesterol. We show that
truncated versions of these toxins fail to form oligomers but still show sigmoidal binding to cholesterol-containing membranes.
The nonlinear response emerges because interactions between bilayer lipids control cholesterol accessibility to toxins in a
threshold-like fashion. Around these thresholds, the affinity of toxins for membrane cholesterol varies by >100-fold, generating
highly cooperative lipid-dependent responses independently of protein-protein interactions. Such lipid-driven cooperativity may
control the sensitivity of many cholesterol-dependent processes.INTRODUCTIONCholesterol-sensing proteins respond to small changes in the
concentration of cholesterol in mammalian cell membranes
with a sharp, switch-like sensitivity (1–3). For example, a
small increase in endoplasmic reticulum (ER) membrane
cholesterol from 5 mol % to 8 mol % of total ER lipids
triggers an all-or-none response from Scap, a cholesterol-
sensing oligomeric membrane protein that controls the
activation of sterol-regulatory element binding proteins
(SREBPs), which are transcription factors that stimulate
lipid synthesis and uptake (1,4). Another example of such
a sensor is perfringolysin O (PFO), a soluble bacterial toxin
that specifically binds to cholesterol-containing membranes
and forms large oligomeric pores (5). Binding of PFO to pu-
rified ER membranes occurs only after the concentration of
cholesterol exceeds a threshold of 5 mol %, precisely the
same concentration at which Scap is activated (2). Binding
of PFO to purified plasma membranes also shows a
threshold response, except that the threshold cholesterol
concentration is shifted to 35 mol % (3). Binding of PFO
to much simpler model membranes composed of just two
components, cholesterol and a phospholipid, also occurs
only after the cholesterol concentration exceeds a threshold
ranging from 20 mol % to 50 mol % depending on the phos-
pholipid headgroup and acyl chain structure (2,6,7).
The molecular basis for these thresholds remains poorly
understood. It is not known whether such highly sigmoidalSubmitted September 22, 2014, and accepted for publication February 12,
2015.
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0006-3495/15/03/1459/11 $2.00responses arise due to allosteric changes in the binding of
cholesterol to Scap or PFO oligomers, or due to properties
of the membrane that affect the chemical activity of choles-
terol and thus its accessibility to Scap or PFO. Determining
the relative contribution of either mechanism is crucial for
understanding the sensitivity of cholesterol sensors and
guiding their use as probes for cholesterol in the membranes
of living cells.
Scap is a polytopic membrane protein, and studying its
interaction with membrane cholesterol is technically chal-
lenging (8). Unlike Scap, PFO is a soluble protein that
does not require detergents for stability and can be easily
produced in large quantities. Moreover, there are two
remarkable similarities in how Scap and PFO detect mem-
brane cholesterol. The first similarity is their common
threshold sensitivity for ER membrane cholesterol. Both
Scap and PFO bind to ER cholesterol only after the choles-
terol concentration exceeds a threshold of 5 mol % of total
lipids (1,2). The second similarity is their identical sterol
structural specificity. Both Scap and PFO bind to choles-
terol, dihydrocholesterol, desmosterol, and b-sitosterol,
but not to epicholesterol, lanosterol, 19-hydroxy-choles-
terol, or 25-hydroxy-cholesterol (2,9). Their common abil-
ity to distinguish between cholesterol and epicholesterol,
a diastereomer that differs only in the orientation of
the sterol 3-hydroxyl group, is especially striking. PFO is
thus a convenient model for investigating the sensitivity of
cholesterol sensors for membrane cholesterol.
PFO is the best-studied member of a large family of
cholesterol-dependent cytolysins (CDCs) that are produced
by more than 25 bacterial species and share a high degreehttp://dx.doi.org/10.1016/j.bpj.2015.02.008
1460 Gay et al.(>45%) of sequence similarity (5,10). To date, high-resolu-
tion crystal structures of the soluble forms of six members
of this family—PFO (11), intermedilysin (12), anthrolysin
O (ALO) (13), suilysin (14), listeriolysin O (15), and
streptolysin O (16)—have been solved. There are no high-
resolution crystal structures of the cholesterol-bound or
oligomeric forms of any member of the CDC family. Never-
theless, extensive biophysical studies of PFO (6,17–19),
combined with a cryo-electron microscopy study of oligo-
mers of another CDC, pneumolysin (20), have revealed
many details of CDC pore formation, as illustrated in the
schematic diagram in Fig. 1 A. CDCs are elongated proteins
that can be divided into four domains (11). The carboxy-
terminal domain, referred to as domain 4 (D4) and shaded
yellow in Fig. 1 A, is necessary and sufficient for binding
to membrane cholesterol (17). This initial binding event
is followed by oligomerization into a circular prepore
complex. Dramatic restructuring involving all four domains
eventually leads to the formation of a transmembraneA
B
C
D
FIGURE 1 Interaction of PFO and ALO with sterol-containing membranes.
(CDCs) with cholesterol-containing membranes. Soluble monomeric CDCs b
undergo large conformational changes to form a membrane-spanning pore. Th
and ALO. A ribbon representation of the a-carbon backbone of the crystal struc
30–390 in PFO; amino acids 46–403 in ALO) in blue, and domain 4 (D4; amino a
hexapeptide sequence (GTTLYP) is shaded red. Underlined residues of this hex
residues in ALO (K46 and S404) that were mutated to cysteines for covalent atta
PFO and ALO. Recombinant wild-type (WT) and mutant (Mut) versions of full
pressed and purified as described in Materials and Methods. Each reaction mixtur
protein and 600 mM liposomes composed of DOPC and varying mole fractions o
room temperature, intrinsic tryptophan fluorescence from the samples was mea
each version of PFO or ALO, the fluorescence from mixtures of protein with li
Biophysical Journal 108(6) 1459–1469b-barrel pore comprised of 35–50 monomers with an inner
diameter of 250–300 A˚. Unfortunately, the elegant studies
cited above do not explain PFO’s threshold sensitivity for
membrane cholesterol. To date, no studies have decoupled
the roles of PFO oligomerization from those of membrane
effects in determining PFO’s sharp sigmoidal binding to
cholesterol-containing membranes.
Here, we addressed this problem by conducting a
detailed study of the threshold cholesterol sensitivities
of two members of the CDC family: PFO and ALO.
Using truncated forms of PFO and ALO that do not form
oligomers, we isolated the role of membrane cholesterol
accessibility in defining the threshold-like sensitivity
of these toxins. We found that the primary trigger for their
switch-like responses is encoded by the lipid composi-
tion of the membrane. Interactions of cholesterol with
membrane phospholipids can modulate the affinities of
PFO and ALO for membrane cholesterol by more than
100-fold, resulting in sharp, switch-like responses. Toxin(A) General model for the interaction of cholesterol-dependent cytolysins
ind to membrane cholesterol, oligomerize on the membrane surface, and
e cholesterol-binding domain is shaded in yellow. (B) Structures of PFO
tures of PFO (11) and ALO (13) is shown with domains 1–3 (amino acids
cids 391–500 in PFO; amino acids 404–512 in ALO) in yellow. A conserved
apeptide are identical in 26 related CDCs (10). Also shown are locations of
chment of fluorescent labels. (C and D) Intrinsic tryptophan fluorescence of
-length (FL) PFO and ALO, as well as D4 of PFO and ALO, were overex-
e, in a total volume of 200 mL of buffer B, contained 4.4 mM of the indicated
f cholesterol (Chol.) or epicholesterol (Epichol.). After incubation for 1 h at
sured (excitation wavelength, 290 nm; emission wavelength, 340 nm). For
posomes containing 0% sterol is normalized to 1.
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this response.MATERIALS AND METHODS
Materials and buffers
We obtained 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-
diphytanoyl-sn-glycero-3-phosphocholine (DPhyPC) from Avanti Polar
Lipids (Alabaster, AL); Dulbecco’s phosphate buffered saline (DPBS)
from Corning (Corning, NY); Alexa Fluor 594 C5 maleimide, dimethyl
sulfoxide (DMSO), Texas Red 1,2-dihexadecanoyl-sn-glycero-3-phosphoe-
thanolamine (TR-DHPE), Marina Blue 1,2-dihexadecanoyl-sn-glycero-3-
phosphoethanolamine (MB-DHPE), and isopropyl-1-thio-b-d-galactopyra-
noside (IPTG) from Invitrogen; cholesterol and tris (2-carboxyethyl)
phosphine (TCEP) from Sigma-Aldrich (St. Louis, MO); epicholesterol
from Steraloids (Newport, RI) and bovine serum albumin (BSA) from
Thermo Fischer Scientific (Waltham, MA). Newborn calf lipoprotein-
deficient serum (LPDS, d < 1.215 g/mL) was prepared by ultracentrifuga-
tion as described previously (21). Buffer A contained 50 mM Tris-HCl
(pH 7.5) and 150 mM NaCl. Buffer B consisted of buffer A supplemented
with 1 mM dithiothreitol (DTT). Buffer C was buffer A supplemented with
1 mM TCEP. Buffer D was DPBS supplemented with 2% (v/v) LPDS and
1 mM EDTA.Expression plasmids
All genetic constructs were cloned into the pRSET B expression vector. A
plasmid containing the gene encoding the signal-peptide deficient PFO
from Clostridium perfringens (amino acids 29–500) in which the sole
cysteine was mutated to alanine (C459A) was a gift from Art Johnson
(Texas A&M University). This construct has been described previously
(6) and is hereafter referred to as PFO-FL. A plasmid containing the gene
encoding a truncated fragment of PFO-FL (amino acids 391–500) was
kindly provided to us by Akash Das (University of Texas Southwestern
Medical Center). This fragment was defined as the fourth of four distinct
structural domains of the soluble form of PFO (11) and was previously
shown to bind to cholesterol-containing membranes without causing mem-
brane lysis (22,23). This construct is hereafter referred to as PFO-D4. The
gene encoding signal-peptide deficient ALO from Bacillus anthracis
(amino acids 35–512) with flanking BamHI and EcoRI restriction sites
was synthesized by GenScript (Piscataway, NJ) with a codon sequence opti-
mized for efficient bacterial overexpression, and provided to us in the
pUC57 cloning vector. This ALO gene was excised and ligated into the
pRSET B expression vector, and this construct is hereafter referred to as
ALO-FL. Using ALO-FL as template, a plasmid encoding a truncated frag-
ment of ALO (amino acids 404–512) was generated by site-directed muta-
genesis (QuikChange II XL Site-Directed Mutagenesis Kit; Agilent). This
fragment of ALOwas defined as D4 of ALO in a study comparing the struc-
tures of the soluble forms of ALO and PFO (13), and is hereafter referred to
as ALO-D4. The PFO-FL, ALO-FL, and ALO-D4 constructs had an NH2-
terminal hexahistidine tag followed by an enterokinase cleavage site. The
PFO-D4 construct had an NH2-terminal octahistidine tag. Mutations in
all four constructs were generated by site-directed mutagenesis. The integ-
rity of each plasmid was verified by DNA sequencing of its entire open
reading frame.Overexpression and purification of recombinant
proteins
Expression plasmids were transformed into BL21 (DE3) pLysS Escherichia
coli-competent cells (Invitrogen), and protein overexpression was carried
out as previously described (6) with the following modifications: PFO-FLand derivatives were induced with 1 mM IPTG at 37C for 3.5 h; ALO-
FL and derivatives were induced with 0.5 mM IPTG at 30C for 16 h;
and PFO-D4, ALO-D4, and derivatives were induced with 1 mM IPTG at
18C for 16 h. A cell pellet from a 6 L bacterial culture was resuspended
in 120 ml of buffer B containing 1 mg/mL lysozyme, 0.4 mg/mL phenylme-
thanesulfonyl fluoride, and six protease inhibitor cocktail tablets (Complete
Mini, EDTA free; Roche, Basil, Switzerland), and incubated at 4C for
30 min. The lysozyme-disrupted cells were lysed using a dounce homoge-
nizer followed by a tip sonicator (Branson, Danbury, CT) and then sub-
jected to 220,000  g centrifugation for 1 h. The resulting supernatant
was loaded on a column packed with Ni-NTA (nickel-nitrilotriacetic
acid) agarose beads (Qiagen, Hilden, Germany). The column was washed
with 10 column volumes of buffer B containing 50 mM imidazole, and
bound proteins were eluted with either buffer B containing 300 mM imid-
azole (PFO-FL, ALO-FL, and derivatives) or with buffer B containing a
linear gradient of 50–300 mM imidazole (PFO-D4, ALO-D4, and deriva-
tives). The eluted fractions with the desired proteins were pooled and
concentrated using an Amicon Ultra centrifugal filter (Millipore, Billerica,
MA; 30,000 MWCO for PFO-FL and ALO-FL, and 10,000 MWCO for
PFO-D4 and ALO-D4) and further purified by gel filtration chromatog-
raphy on a Tricon 10/300 Superdex 200 column (GE Healthcare, Uppsala,
Sweden) equilibrated with buffer B. Protein-rich fractions were pooled,
concentrated to 1–10 mg/mL, and stored at 4C until use. Protein con-
centrations were measured using a NanoDrop instrument (Thermo Fisher
Scientific) or by using a bicinchoninic acid kit (Pierce).Labeling of cysteine-substituted proteins
with fluorescent groups
Derivatives of ALO containing single cysteines were purified as described
above except that the final gel filtration step was carried out on a column
equilibrated with buffer C, which contains TCEP instead of DTT. In a
typical 200 mL labeling reaction, 20 nmoles of protein (100 mM) was
incubated with 200 nmoles of Alexa Fluor 594 C5-maleimide. After incu-
bation for 16 h at 4C, the reaction was quenched by addition of DTT to
a final concentration of 10 mM. Free dye was separated from labeled
protein by passing the reaction mixture twice through Zeba spin desalting
columns (Pierce, Waltham, MA; 40,000 MWCO for ALO-FL and 7,000
MWCO for ALO-D4) equilibrated in buffer B. Finally, labeled proteins
were subjected to gel filtration chromatography as described above to
remove any residual free dye and to ensure that no protein aggregation
had occurred. Protein-rich fractions were pooled, concentrated, and stored
at 4C until use. The final protein concentration and extent of protein label-
ing were measured on a Nanodrop instrument using the following parame-
ters: reported ε590 of 100,000 M
1cm1 for Alexa Fluor 594 (Invitrogen,
Waltham. MA) and calculated ε280 of 61,000 and 35,000 M
1cm1 for
ALO-FL and ALO-D4, respectively. The degree of protein labeling ranged
from 0.4 to 0.9.Preparation of liposomes
All lipids were used without further purification. Mixtures containing the
indicated proportions of phospholipids and sterols (from chloroform stock
solutions) were evaporated to dryness under a steady stream of nitrogen gas
and stored under vacuum for at least 16 h. A trace amount (<0.2 mol %) of a
fluorescently labeled phospholipid (TR-DHPE for assays with unlabeled
proteins, MB-DHPE for assays with Alexa-594 labeled proteins) was
included for detection and quantification of liposomes. The dried lipid
mixtures were hydrated by adding 500 mL of buffer A (final lipid concen-
tration, 800 mM), agitated on a vortexer for 1 h, and subjected to three
freeze-thaw cycles (one cycle ¼ 60 s in a liquid nitrogen bath, 3 min in a
room temperature water bath). The resulting lipid dispersions were placed
in a water bath at 37C and subjected to sonication for 15 min followed by
a 15 min pause for cooling (two cycles). Finally, the lipid mixtures wereBiophysical Journal 108(6) 1459–1469
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homogeneous unilamellar liposomes. Liposomes were stored at 4C and
used within 5 days. Spot checks were carried out to verify cholesterol con-
centrations in liposomes as described previously (2). In all cases, the
measured concentration of cholesterol in liposomes was within 5 mol %
of the expected values.Assays for interaction of purified proteins with
liposomes
Reaction mixtures (200 mL) containing 600 mM liposomes (total lipid) and
4.4 mM protein in buffer B were set up in 1.5 mL tubes (Phenix Research
Products, Candler, NC). After incubation for 1 h at room temperature,
a portion of each reaction mixture (100 mL) was transferred to a 96-well
plate (black, flat-bottom, nonbinding; Greiner Bio-One, Monroe, NC) and
intrinsic tryptophan fluorescence was measured using a microplate reader
(Tecan, Ma¨nnedorf, Switzerland) (excitation wavelength, 290 nm; emission
wavelength, 340 nm; band pass, 5 nm for each). A portion of each reaction
mixture (20 mL) was mixed with SDS loading buffer, heated for 10 min
at 37C, and subjected to SDS-PAGE. Proteins were visualized with
Coomassie Brilliant Blue R-250 stain (Bio-Rad, Hercules, CA). In assays
measuring the affinity of PFO for membrane cholesterol, reaction mixtures
(1 mL) containing 100 nM PFO and 0–500 mM liposomes, all in buffer B,
were set up in 1.5 mL tubes. After incubation for 2 h at room temperature,
40 mL of Ni-NTA agarose bead slurry that had been washed twice and
resuspended in 100 mL of buffer B was added to each reaction. After
additional incubation for 1 h at room temperature, the His6-tagged PFO
was pelleted by centrifugation at 16,000  g for 5 min. The supernatant
was discarded and the Ni-bound PFO was eluted by the addition of
20 mL of buffer B supplemented with 500 mM imidazole. After addition
of 4 mL of 5 SDS loading buffer and heating for 10 min at 37C, samples
were centrifuged at 16,000  g for 5 min and the resulting supernatant
was subjected to SDS-PAGE. Proteins were visualized with Coomassie
Brilliant Blue R-250 stain. Densitometry analysis was carried out using
ImageJ software (NIH, version 1.36B, Bethesda, MD). For assays in
which fluorescently labeled proteins were used, reaction mixtures
(120 mL) containing 67 mM liposomes (total lipid), 0.5 mM fluorescently
labeled protein, and 0–10 mM unlabeled protein in buffer B were set up
in 1.5 mL tubes. After incubation for 1 h at room temperature, a portion
of each reaction mixture (100 mL) was transferred to a 96-well plate
(Greiner Bio-One), and fluorescence was measured using a microplate
reader (excitation wavelength, 590 nm; emission wavelength, 617 nm;
band pass, 2.5 nm for each).Hemolysis assays
For a typical assay, 4 mL of fresh rabbit blood was centrifuged at 120  g
for 10 min and the erythrocyte pellet was resuspended in 4 mL of ice-cold
buffer D. After gentle mixing by hand, the mixture was centrifuged at
500  g for 10 min and the resulting pellet was again resuspended in
4 mL of ice-cold buffer D. After gentle mixing by hand, the mixture was
centrifuged at 1000 g for 20 min and the resulting pellet was resuspended
in 36 mL of ice-cold buffer D. Standard hemolysis reaction mixtures
(500 mL) containing 450 mL of erythrocytes (washed and diluted as
described above) and 50 mL of buffer A containing protein (0–300 nM
final concentration) were set up in 1.5 mL tubes. In some hemolysis assays,
proteins were preincubated with cholesterol or epicholesterol dissolved
in DMSO (4% (v/v) final concentration) for 1 h at room temperature
before addition of erythrocytes. After incubation for 10 min at 37C, the
mixtures were centrifuged at 380  g for 15 min and a portion of the
supernatant (100 mL) was transferred to a 96-well plate (clear, flat-bottom;
Evergreen Scientific, Los Angeles, CA). The extent of hemolysis was
quantified using a microplate reader by measuring the absorbance of
released hemoglobin at 540 nm.Biophysical Journal 108(6) 1459–1469Data analysis
The data points in all plots of Figs. 1, 2, 3, 4, and 5 represent the mean of
three independent assays (except for Fig. 3 B, which shows the average of
two independent assays). Error bars represent the mean 5 SE. When not
visible, error bars are smaller than the size of the data symbols. In Fig. 4,
the binding curves represent a weighted least-squares fit of a sigmoidal
function to the data points. The best-fit values of switch-points (cholesterol
mole percentages where the normalized Trp fluorescence equals 0.5) for the
various protein/phospholipid pairs are 41 mol % for PFO-FL/DOPC;
31 mol % for PFO-FL/DPhyPC; 26 mol % for ALO-FL/DOPC; 17 mol %
for ALO-FL/DPhyPC; 45 mol % for PFO-D4/DOPC; 27 mol % for
PFO-D4/DPhyPC; 45 mol % for ALO-D4/DOPC; and 27 mol % for
ALO-D4/DPhyPC). In Fig. 5, B and D, the curves for PFO-FL oligomeri-
zation, and inhibition of PFO-FL and ALO-FL hemolysis by cholesterol
represent fits to a one-site receptor-ligand binding model. The best-fit
values for half-maximal oligomerization in Fig. 5 B are 11 mM and
16 mM for 40 mol % cholesterol and 50 mol % cholesterol, respectively,
and >1000 mM for 20 mol % and 30 mol % cholesterol. The best-fit
values for 50% inhibition in Fig. 5 D are 108 nM for ALO-FL and
97 nM for PFO-FL.RESULTS AND DISCUSSION
Cholesterol switch-points of PFO and ALO:
identical for D4s, but different for full-length
versions
The crystal structures of PFO and ALO monomers are
shown in Fig. 1 B with their carboxy-terminal D4s shaded
yellow. These proteins share ~70% sequence identity and
a common elongated, b-sheet-rich architecture. Previous
studies showed that D4s from PFO and ALO were sufficient
for binding to membrane cholesterol, but were unable to
form oligomers or membrane pores (23,24). These earlier
studies suggested that a comparative study of full-length
(FL) versus D4 fragments of CDCs might shed light
on the role of oligomerization in determining the threshold
cholesterol sensitivity of CDCs. To this end, we expressed
FL and D4 versions of both PFO and ALO, all with
amino-terminal His-tags, in bacteria. We purified the
resulting recombinant proteins (hereafter referred to as
PFO-FL, PFO-D4, ALO-FL, and ALO-D4) to homogeneity
using nickel chromatography followed by gel filtration
chromatography. We then adapted many of the assays
established by the Johnson and Tweten groups for PFO-FL
(5,6,17–19) and extended them to study the various domains
of PFO and ALO.
PFO-FL contains seven Trp residues, six of which are
located in its D4, and binding to membranes results in a
2- to 3-fold increase in its Trp fluorescence (2,25,26). Since
ALO-FL contains six Trp residues (five in its D4) at similar
locations compared with PFO-FL, we monitored the
intrinsic Trp fluorescence of both proteins to measure their
binding to cholesterol-containing membranes. Initially,
we used model membranes composed of binary mixtures
of DOPC and cholesterol, and varied the mole fraction of
cholesterol while keeping the total amount of membranes
constant in each reaction. In this approach, changes in
A B
C D
FIGURE 2 Oligomerization and pore formation
by PFO and ALO after binding to cholesterol-con-
taining membranes. (A and B) Coomassie staining.
Aliquots (10% of total) of the reaction mixtures
from Fig. 1, C and D, containing recombinant
FL or D4 of PFO and ALO with membranes
containing DOPC and varying mole fractions of
cholesterol were subjected to SDS-PAGE. Proteins
were visualized with Coomassie Brilliant Blue
R-250 stain. The molecular masses of protein stan-
dards are indicated. Arrows indicate the interface
between stacking and resolving gels. (C and D)
Hemolysis assays. Each reaction mixture, in a final
volume of 500 mL, contained varying amounts
of the indicated version of PFO, ALO, or BSA,
and 450 mL rabbit erythrocytes that had been
washed and diluted as described in Materials
and Methods. After incubation for 10 min at
37C, the extent of hemolysis was quantified by
measuring the release of hemoglobin (absorbance
at 540 nm). The dashed line represents the amount
of hemoglobin that was released after treatment
with 1% (w/v) Triton-X 100 detergent.
Sensors of Membrane Cholesterol 1463membrane cholesterol content are accompanied by an oppo-
site change in the content of DOPC.
As shown in previous studies (2,6,7) and Fig. 1 C, when
PFO-FL was incubated with liposomes containing
increasing mole fractions of cholesterol, its Trp fluorescence
increased by ~3-fold in a sharp, sigmoidal fashion, with a
half-maximum at 41 mol % cholesterol. Hereafter, we use
the term ‘‘switch-point’’ to refer to the cholesterol mole
fraction corresponding to the midpoint of the switch-likeA B C
of 50 mol %DOPC and 50 mol % cholesterol, and varying amounts of the indicat
proteins. Reaction mixtures, in a volume of 100 mL buffer B, contained 3.6 mM
varying mole fractions of cholesterol or epicholesterol. After incubation for 1 h
wavelength, 590 nm; emission wavelength, 617 nm; band pass, 2.5 nm fo
290 nm; emission wavelength, 340 nm) was measured. For each protein, fluore
is normalized to 1.increase in Trp fluorescence, an indicator of CDC binding
to membranes (see Materials and Methods for details on
curve fitting). When ALO-FL was incubated with DOPC-
cholesterol membranes, its Trp fluorescence increased by
~2-fold in a sharp, sigmoidal fashion as well, but its
switch-point was shifted to 26 mol % cholesterol. PFO-FL
and ALO-FL showed no binding to membranes containing
epicholesterol, even when the mole fraction of this diaste-
reomer of cholesterol reached 60 mol %. Binding was alsoFIGURE 3 Interaction of fluorescently labeled
ALO with sterol-containing membranes. Recom-
binant ALO-FL and ALO-D4 were overexpressed
and purified, and fluorescently labeled versions
(fALO-FL and fALO-D4) were generated as
described in Materials and Methods. (A and C)
Alexa 594 fluorescence of the labeled proteins.
Reaction mixtures, in a final volume of 120 mL
buffer B, contained 0.5 mM of the indicated fluo-
rescently labeled protein and 67 mM liposomes
comprised of DOPC and varying amounts of
cholesterol (Chol.) or epicholesterol (Epi.) (A) or
0.5 mM fALO-FL, 67 mM liposomes comprised
ed unlabeled protein (C). (B) Intrinsic tryptophan fluorescence of the labeled
of the indicated protein and 600 mM liposomes composed of DOPC and
at room temperature, Alexa Fluor 594 fluorescence (A and C) (excitation
r each) or intrinsic tryptophan fluorescence (B) (excitation wavelength,
scence from mixtures of protein with liposomes containing 0% cholesterol
Biophysical Journal 108(6) 1459–1469
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FIGURE 4 Cholesterol thresholds for ALO and PFO are determined
by membrane phospholipids. (A and B) Recombinant FL and D4 of PFO
and ALO were overexpressed and purified as described in Materials and
Methods. Each reaction mixture, in a total volume of 200 mL of buffer B,
contained 4.4 mM of the indicated protein and 600 mM liposomes composed
of DOPC or DPhyPC and varying mole fractions of cholesterol. After incu-
bation for 1 h at room temperature, the intrinsic tryptophan fluorescence
of the samples was measured (excitation wavelength, 290 nm; emission
wavelength, 340 nm). For each combination of protein and phospholipid,
fluorescence values were normalized to range from 0 to 1.
1464 Gay et al.abolished when a conserved hexapeptide sequence,
GTTLYP (shaded red in Fig. 1 B), was mutated to GTAAYP
in PFO-FL and to AAAAAA in ALO-FL. The threonine-
leucine pair within this hexapeptide region was previously
shown to be critical for the binding of PFO and two other
CDCs (streptolysin and pneumolysin) to cholesterol-con-
taining membranes (17). Mutation of just the TL pair in
ALO-FL to AA only partially affected ALO-FL’s ability
to bind to cholesterol-containing membranes.
We then measured the interaction of truncated D4
fragments of PFO and ALO with DOPC-cholesterol mem-
branes. As shown in Fig. 1 D, the Trp fluorescence
of PFO-D4 increased by ~2.5-fold in a sigmoidal fashion,
with a switch-point at 45 mol % cholesterol, which is
slightly shifted from the 41 mol % switch-point observed
for PFO-FL. The Trp fluorescence of ALO-D4 also
increased by ~2.5-fold in a sigmoidal fashion, with a
switch-point at 45 mol % cholesterol, which is significantly
shifted from the 26 mol % switch-point observed for ALO-
FL. Remarkably, although the switch-points for PFO-FL
and ALO-FL in Fig. 1 C differed dramatically (41 mol %
cholesterol versus 26 mol % cholesterol), the switch-points
for PFO-D4 and ALO-D4 were identical (45 mol % choles-
terol). Like their FL counterparts, PFO-D4 and ALO-D4
also showed no binding to membranes containing epicholes-
terol. Introducing the same mutations described above for
PFO-FL and ALO-FL into PFO-D4 and ALO-D4 also
abolished binding.D4s of PFO and ALO do not form oligomers
We next sought to determine whether the dramatic differ-
ence in cholesterol sensitivity between these proteins wasBiophysical Journal 108(6) 1459–1469related to differences in their ability to form oligomers.
To assay for CDC oligomerization, we took advantage of
a previous observation that CDC oligomers are resistant to
denaturation by SDS and can be distinguished from CDC
monomers by their slower electrophoretic mobility during
SDS-PAGE (2,6). As shown in Fig. 2 A (top gel), when mix-
tures of PFO-FL and DOPC-cholesterol liposomes were
subjected to SDS-PAGE, PFO-FL migrated primarily as
an ~50 kDa species (calculated molecular mass: 57 kDa)
for cholesterol mole fractions up to 40 mol %. At higher
mole fractions of cholesterol, the ~50 kDa monomeric
form of PFO-FL was significantly diminished and the ma-
jority of PFO-FL was found as a slower-migrating species
(>250 kDa), consistent with a large oligomer. Fig. 2 B
(top gel) shows similar results for mixtures of ALO-FL
and DOPC-cholesterol liposomes. A major fraction of
ALO-FL electrophoresed as a slow-migrating oligomer
(>250 kDa) rather than an ~50 kDa monomer (calculated
molecular mass: 56 kDa), only when membrane cholesterol
exceeded 25 mol %. The cholesterol mole fractions at which
oligomeric forms became dominant (40–45 mol % for PFO-
FL; 25–30 mol % for ALO-FL) exactly matched the switch-
points observed using the Trp fluorescence assay (Fig. 1 C).
In contrast, when we subjected mixtures of PFO-D4 or
ALO-D4 and DOPC-cholesterol liposomes to SDS-PAGE,
we observed only their monomeric forms at ~15 kDa (calcu-
lated molecular masses: PFO-D4, 14 kDa; ALO-D4,
16 kDa), even at the highest cholesterol mole fraction of
60 mol % (Fig. 2, A and B, bottom gels).
Oligomerization of CDCs on the surface of cholesterol-
containing membranes eventually leads to formation of a
membrane-spanning pore. We used a hemolysis assay to
test the ability of FL and D4 fragments of PFO and ALO
to form pores in rabbit erythrocytes. As shown in Fig. 2
C, PFO-FL caused complete hemolysis at a concentration
of 3 nM, whereas PFO-D4 or a control protein (BSA) caused
no hemolysis, even when added at a concentration of
300 nM. Similarly, as shown in Fig. 2 D, ALO-FL caused
complete hemolysis at a concentration of 1 nM, whereas
ALO-D4 or BSA did not lyse red cells, even when added
at a concentration of 300 nM.
Taken together, the tryptophan fluorescence, gel-shift,
and hemolysis assays show that when membrane cholesterol
exceeds a threshold concentration, the FL versions of PFO
and ALO undergo a transition from a soluble to a mem-
brane-bound form (state I to state II; Fig. 1 A), and then
oligomerize to finally form a membrane-spanning pore
(states III and IV; Fig. 1 A). The D4 versions of PFO and
ALO also bind to cholesterol-rich membranes, but do not
form oligomers or pores. The gel-shift assays used to assess
oligomerization are not conclusive, since it is possible that
D4 oligomers are broken down more readily than FL oligo-
mers by the denaturing conditions of SDS-PAGE. To
study the oligomeric properties of CDCs using a different
approach, we developed a fluorescence-quenching assay
AB
C
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FIGURE 5 Affinity of PFO and ALO for choles-
terol is determined by membrane phospholipids.
Recombinant PFO-FL and ALO-FL were overex-
pressed and purified as described in Materials
and Methods. (A and B) Affinity of PFO-FL for
membrane cholesterol. Each reaction mixture, in
a total volume of 1 mL of buffer B, contained
100 nM PFO-FL (5.7 mg) and varying amounts of
liposomes composed of DOPC and the indicated
amounts of cholesterol. (A) After incubation for
2 h at room temperature, PFO-FL was concentrated
to a volume of 20 mL as described in Materials and
Methods, and the entire amount of protein was
subjected to SDS-PAGE. Lane 1 (I) in each gel
contains 5.7 mg of PFO-FL (input amount) as a
reference to judge the efficiency of PFO-FL con-
centration by Ni beads. Proteins were visualized
with Coomassie Brilliant Blue R-250 stain. The
molecular masses of protein standards are shown.
Arrows indicate the interface between stacking
and resolving gels. O, membrane-bound oligo-
meric form of PFO; M, free monomer form of
PFO. (B) Gels were scanned and densitometric
analysis was carried out to determine the percent-
age of the oligomeric, membrane-bound form of
PFO relative to the total (membrane-bound olig-
omer plus free monomer). (C) Binding kinetics.
Each reaction mixture, in a total volume of
200 mL of buffer B, contained 4.4 mM of PFO-FL
and 600 mM liposomes composed of DOPC and the indicated amounts of cholesterol. After incubation at room temperature for the indicated times, intrinsic
tryptophan fluorescence from the samples was measured (excitation wavelength, 290 nm; emission wavelength, 340 nm). The fluorescence from mixtures of
PFO-FL with liposomes containing 0% sterol is normalized to 1. (D) Binding of DMSO-solubilized sterols to PFO-FL and ALO-FL. Each reaction mixture,
in a final volume of 50 mL, contained either ALO-FL (1 nM) or PFO-FL (3 nM), and varying amounts of cholesterol or epicholesterol dissolved in DMSO
(4% (v/v) final concentration). After incubation for 1 h at room temperature, 450 mL of rabbit erythrocytes (washed and diluted as described in Materials
and Methods) was added to each reaction mixture. After incubation for 10 min at 37C, the extent of hemolysis was quantified by measuring the release
of hemoglobin (absorbance at 540 nm).
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the sole cysteine in ALO (C472) to alanine and introduced
single cysteines near the NH2-terminii of cysteine-less
ALO-FL (K46C) and ALO-D4 (S404C). We then covalently
attached fluorophores (Alexa Fluor 594) to the sulfhydryl
groups of these cysteine residues. These fluorescently
labeled proteins are hereafter referred to as fALO-FL and
fALO-D4. By placing fluorescent reporters near the NH2-
terminus, far from the COOH-terminal tip that is involved
in cholesterol binding, we hoped to gain insight into post-
binding conformational changes involving oligomerization.
As shown in Fig. 3 A, when fALO-FL was incubated
with DOPC-cholesterol liposomes, its Alexa 594 fluores-
cence was constant until membrane cholesterol reached
25 mol %. At higher cholesterol mole fractions, Alexa
594 fluorescence decreased by >75% in a sharp, sigmoidal
fashion. No such reduction in Alexa 594 fluorescence was
observed when fALO-FL was incubated with liposomes
containing epicholesterol. In contrast to the dramatic,
cholesterol-specific quenching observed for fALO-FL, no
significant change in Alexa 594 fluorescence was observed
when fALO-D4 was incubated with DOPC-cholesterol
liposomes, even when the membranes contained 60 mol %cholesterol. The Trp fluorescence assays in Fig. 3 B show
that fALO-D4 binds to DOPC-cholesterol membranes
with a switch-point of ~45 mol % cholesterol, similar to
what was observed for unlabeled ALO-D4 (Fig. 1 D), thus
confirming the activity of this fluorescently labeled protein.
The Trp fluorescence assays also show that fALO-FL binds
to DOPC-cholesterol membranes with a switch-point of
~30 mol % cholesterol and does not bind to membranes
containing epicholesterol, similar to what was observed
for unlabeled ALO-FL (Fig. 1 C). The correlation between
changes in Trp and Alexa 594 fluorescence of fALO-FL,
but not of fALO-D4, is consistent with oligomerization of
membrane-bound fALO-FL, but not of membrane-bound
fALO-D4.
If quenching of fALO-FL fluorescence was due to the
close proximity of Alexa 594 fluorophores in membrane-
bound oligomers, the addition of unlabeled ALO-FL during
the reaction would be expected to result in mixed oligomers
and relieve proximity-based quenching. As shown in Fig. 3
C, when fALO-FL was incubated with DOPC-cholesterol
liposomes containing 50 mol % cholesterol, its Alexa 594
fluorescence was quenched by ~60% relative to when it
was incubated with liposomes containing no cholesterol.Biophysical Journal 108(6) 1459–1469
1466 Gay et al.As increasing amounts of unlabeled ALO-FL were added
to the reaction, the Alexa 594 fluorescence gradually
increased, and complete recovery to unquenched levels
occurred when unlabeled ALO-FL concentrations were
four times that of fALO-FL. In contrast, no recovery of
quenched Alexa 594 fluorescence was observed when unla-
beled ALO-D4 or BSA was added to the reaction. These
results suggest that ALO-D4 cannot form self-oligomers
after binding to membrane cholesterol or be incorporated
efficiently into oligomers of ALO-FL. The fluorescence of
a labeled version of PFO-FL (D30C) is also quenched in a
sharp sigmoidal fashion when incubated with DOPC-
cholesterol liposomes containing >40 mol % cholesterol.
So far, however, we have been unable to generate a stable
fluorescently labeled version of PFO-D4 to study its oligo-
meric properties using this quenching assay. Single cysteine
residues were introduced at 10 locations in cysteine-less
PFO-D4 (N395, K417, E418, Y432, Q433, D469, S472,
Y474, D475, and N481), but in all cases the purified recom-
binant protein precipitated and was unusable. Nonetheless,
the fluorescence quenching studies with ALO support the
gel-based results in Fig. 2, which show that FL versions of
CDCs form oligomers after binding cholesterol-containing
membranes, whereas D4 fragments do not.Cholesterol switch-points for D4s of PFO
and ALO depend on the bilayer phospholipid
Although they did not form oligomers, PFO-D4 and ALO-
D4 showed a sharp, sigmoidal cholesterol dependence in
binding to DOPC-cholesterol membranes, with identical
switch-points at 45 mol % cholesterol (Fig. 1 D). To test
whether this common switch-point reflects phospholipid-
dependent accessibility of cholesterol in membranes, we
changed the bulk phospholipid from DOPC (Tm ¼ 2C)
to DPhyPC (Tm<120C). The Tm is a convenient measure
of the ordering tendency of phospholipid acyl chains: the
lower the Tm, the lower the affinity for cholesterol (27).
As shown by the Trp fluorescence assays in Fig. 4 A, both
PFO-D4 and ALO-D4 bound to DPhyPC-cholesterol
membranes in a sharp, sigmoidal fashion. Remarkably, their
switch-points for DPhyPC-cholesterol membranes were
also identical, but at 27 mol % cholesterol, which is signif-
icantly lower than the identical 45 mol % switch-point
observed for their binding to DOPC-cholesterol membranes
(data for DOPC are replotted here from Fig. 1D in a normal-
ized form). As shown in Fig. 4 B, when we studied the inter-
action of PFO-FL and ALO-FL with DPhyPC-cholesterol
membranes, we found that the binding of these proteins
also showed shifts in switch-points to lower cholesterol
mole fractions (31 mol % for PFO-FL, 17 mol % for
ALO-FL; data for DOPC are replotted here for reference
from Fig. 1 C). Whereas the binding curves for PFO-D4
and ALO-D4 to cholesterol-containing membranes collapse
into phospholipid-specific groups, the binding curvesBiophysical Journal 108(6) 1459–1469for PFO-FL and ALO-FL show a wider distribution
of switch-points because oligomerization enhances their
cholesterol sensitivity. The variation in switch-points
(by <10 mol % cholesterol) observed for mutant versions
of PFO-FL (28) is likely due to differences in their
oligomerization.Apparent affinities of PFO and ALO
for cholesterol are determined by
membrane composition
The experiments described so far show that CDC binding to
membrane cholesterol is sensitive to the mole fraction or
surface density of cholesterol in membranes. To further un-
derstand the affinity of CDCs for membrane cholesterol, we
designed a set of experiments in which we fixed the surface
density (mole fraction) of cholesterol in membranes and
varied the amount of cholesterol in the reaction solution
by changing the total amount of membranes. In these exper-
iments, we used the gel-shift assay of Fig. 2 A to monitor the
interaction of PFO-FL with DOPC membranes containing
cholesterol at levels both above and below the 41 mol %
switch-point for this protein-phospholipid pair (Figs. 1 C
and 2 A). The extent of oligomer formation in the Coomas-
sie-stained gels shown in Fig. 5 A was quantified by densi-
tometry and plotted in Fig. 5 B as a function of total
cholesterol concentration in the reaction.
When we subjected mixtures of PFO-FL and increasing
amounts of liposomes containing 20 mol % cholesterol to
SDS-PAGE, we observed that most of the PFO-FL (90%
of total) migrated as a monomeric species, even at the high-
est total concentration of cholesterol (100 mM). Similar
behavior was observed when the liposomes contained
30 mol % cholesterol. When the mole fraction of cholesterol
in liposomes increased to 40 mol % and 50 mol %, signifi-
cant oligomer formation of PFO-FL occurred when the
cholesterol concentration rose above 5 mM. At cholesterol
concentrations of 100 mM, 30–60% of PFO-FL was found
in its slower-migrating oligomeric form. These data show
that the apparent affinity of PFO-FL for DOPC-cholesterol
membranes depends on the lipid composition, ranging
from very little affinity (>1000 mM) when the mole fraction
of cholesterol is 20 mol % and 30 mol % to an affinity of 11
mM and 16 mM when the mole fraction of cholesterol is
40 mol % and 50 mol %, respectively. To test whether this
context-dependent affinity arose due to kinetic differences,
we used the Trp fluorescence assay to measure the time
course of PFO-FL binding to DOPC-cholesterol mem-
branes. As shown in Fig. 5 C, PFO-FL rapidly bound to
membranes containing 40 mol % and 50 mol % cholesterol
with half-maximal binding at ~15 min. However, no binding
of PFO-FL was observed when it was incubated with mem-
branes containing 20 mol % and 30 mol % cholesterol, even
when the reaction time exceeded 1000 min. Similar kinetics
were observed for the binding of PFO-FL to membranes
Sensors of Membrane Cholesterol 1467composed of palmitoyl-oleoyl phosphatidylcholine and
cholesterol (26).
Our studies so far highlight the role of the lipid bilayer
membrane in determining the sensitivity of CDCs for mem-
brane cholesterol. To study the affinity of CDCs for choles-
terol without competing interactions from phospholipids,
we designed a solution-binding assay in which cholesterol
was not immersed in a lipid bilayer. We took advantage of
early observations that hemolysis by CDCs can be inhibited
by preincubating the toxin with cholesterol in organic sol-
vents (5). As shown in Fig. 2, C and D, incubation of rabbit
erythrocytes with PFO-FL (3 nM) or ALO-FL (1 nM) re-
sulted in complete hemolysis. We preincubated PFO-FL
and ALO-FL with cholesterol dissolved in DMSO before
addition to rabbit erythrocytes, and measured the subse-
quent inhibition of hemolysis. As shown in Fig. 5 D, hemo-
lysis was completely inhibited by preincubation of PFO-FL
and ALO-FL with 250 nM cholesterol. No inhibition of
hemolysis was observed after preincubation with epicholes-
terol, even at the highest concentration of 3 mM. Half-
maximal inhibition of hemolysis, which can be related to
a solution affinity of PFO and ALO for cholesterol, occurred
at similar concentrations of 97 nM and 108 nM, respec-
tively. These affinities are only a rough estimate, since a
large fraction of cholesterol added to the aqueous phase
likely becomes rapidly insoluble and inaccessible. The var-
ied threshold-like cholesterol sensitivities observed in Fig. 4
due to differences in cholesterol sequestration by membrane
phospholipids, or to differences in PFO and ALO oligomer-
ization on membranes, were no longer observed when the
affinity of PFO and ALO for cholesterol was measured in
this nonmembrane context.CONCLUSIONS
We have shown that the switch-like sensitivity of choles-
terol-sensing bacterial toxins for membrane cholesterol
arises primarily due to properties of the lipid bilayer. Inter-
actions with membrane phospholipids control the accessi-
bility of membrane cholesterol to soluble sensors such as
PFO and ALO. After binding to accessible cholesterol at
the surface of membranes, the membrane-bound toxins are
stabilized by large-scale oligomerization. This complex
interplay among lipid-lipid, lipid-protein, and protein-pro-
tein interactions serves to fine-tune the final varied sensitiv-
ities of PFO and ALO for cholesterol in membranes.
We were able to elucidate the initial sensing of membrane
cholesterol by PFO and ALO without the complications of
protein oligomerization by engineering nonoligomerizing,
truncated versions of these proteins: PFO-D4 and ALO-
D4. Figs. 1, 2, 3, and 4 show that although they did not
form oligomers, PFO-D4 and ALO-D4 bound to choles-
terol-containing membranes in a sharp, sigmoidal manner.
The concentration of cholesterol at which this switch-like
transition in binding occurs is determined by the phospho-lipid structure (2,6,7). The absolute specificity for choles-
terol over its diastereomer epicholesterol suggests to us a
specific binding site in the ~110 amino acid D4 fragments
of PFO and ALO. Positive cooperativity between multiple
cholesterol binding sites in these nonoligomerizing D4
fragments could be a source of this sigmoidal behavior;
however, we think this explanation is unlikely, as mutation
of just a threonine-leucine pair in PFO-D4 to alanines
completely abolishes membrane binding (see Fig. 1).
Instead, we propose that the sigmoidal binding of PFO-D4
and ALO-D4 to cholesterol-containing membranes is deter-
mined by the accessibility of cholesterol at the surface of
membranes.
The binding reaction of PFO-D4 or ALO-D4 to mem-
brane cholesterol can be conceptualized as a two-step reac-
tion. The first step involves an equilibrium between
cholesterol dissolved in the lipid bilayer membrane and
cholesterol in the water layer at the surface of a lipid bilayer.
Since cholesterol is virtually insoluble in water, this interfa-
cial cholesterol could partially project into the bilayer-asso-
ciated water layer without fully escaping the bilayer. The
fraction of cholesterol molecules that make excursions
into this juxtamembranous water layer is controlled by un-
derlying interactions with membrane phospholipids, and is
a measure of the chemical activity of cholesterol in the
membrane. This first step is purely a feature of the lipid
bilayer. The second step occurs in the aqueous phase and in-
volves the binding of water-soluble PFO-D4 or ALO-D4 to
cholesterol in the water-layer at the membrane periphery. In
this model, the toxin molecules can be considered to be in a
competitive binding equilibrium with the phospholipids
for bilayer cholesterol (2). In aqueous solution, akin to the
second step of this reaction scheme, the apparent binding
affinity of PFO for cholesterol in the water phase is high
(~100 nM, as shown in Fig. 5 D). However, as shown in
Fig. 5 B, when cholesterol-phospholipid interactions in bila-
yers are included, the apparent binding affinity of PFO is
much weaker (~10 mM). In the extreme case where mem-
brane cholesterol is below the switch-point concentration,
interactions with phospholipids dominate the reaction and
there is very little apparent affinity of PFO for membrane
cholesterol (>1000 mM). The sigmoidal dependence for
PFO and ALO binding to membranes clearly involves the
chemical activity of cholesterol, and this could dominate
the reaction even if the binding of toxins to membranes is
not reversible and/or involves toxin oligomerization.
The chemical activity of cholesterol, which controls its
surface accessibility to sensor proteins, generally increases
as the concentration of cholesterol increases, but it can be
severely suppressed at lower concentrations in a sigmoidal
fashion due to interactions with bilayer phospholipids (com-
plex formation) (2,29,30). Theoretical studies have shown
that the cooperative formation of oligomers of such com-
plexes can further sharpen the sigmoidal change in chemical
activity, making it more threshold-like (2,30). This simple,Biophysical Journal 108(6) 1459–1469
1468 Gay et al.intuitive model of complex formation has been extremely
useful in accounting for many physical chemical properties
of membranes (2,29–33); however, such complexes have not
been isolated. This may not be surprising, because molecu-
lar complexes in liquids have been described with relatively
well-defined structures but very short lifetimes (<10 ps)
(34). A well-defined specific structure for phospholipid-
cholesterol complexes may be unlikely, since sharp changes
in chemical activities are observed for a wide variety of
phospholipid and sterol structures (2,31,35). Other models
that consider nonrandom arrangements of cholesterol in
the bilayer could also result in sharp changes in its chemical
activity (36,37). Phase separations provide another possible
mechanism for triggering sharp changes in the chemical
activity of membrane cholesterol; however, no liquid phase
separations have been observed in the simple DOPC-
cholesterol and DPhyPC-cholesterol membranes used here
(38,39). Regardless of the mechanism that modulates the
chemical activity of cholesterol in membranes, it is clear
that a property of the lipid bilayer itself can be a key regu-
lator of cholesterol-sensing proteins.
Disappointingly, no high-resolution structures of PFO or
ALO bound to cholesterol are available to test our proposed
reaction scheme. However, it is worth examining the struc-
ture of cholesterol-bound Osh4, a soluble protein from yeast
that is related to the family of mammalian oxysterol-binding
protein (OSBP)-related proteins (ORPs) that have been
implicated in cholesterol homeostasis (40). The structure
of cholesterol-Osh4 shows no direct hydrogen bonds be-
tween Osh4 amino acid side chains and the hydroxyl group
or any other part of cholesterol; instead, the cholesterol
is bound through water-mediated interactions. In contrast,
the crystal structure of cholesterol-bound N-terminal
domain of human Niemann Pick C1 (NPC1), a soluble pro-
tein that is involved in cholesterol transport from lysosomes,
shows a snug binding pocket and direct close contacts
between NPC1 amino acid side chains and the hydroxyl
group and tetracyclic steroid nucleus of cholesterol (41).
It remains to be seen whether cholesterol sensors such as
ALO and PFO employ either one of these strategies for
binding to membrane cholesterol.
The chemical activity of membrane cholesterol likely
controls its surface accessibility to other soluble molecules
such as cholesterol oxidase and cyclodextrin (30,31,42).
Of particular interest is a recent report that the choles-
terol-binding site in Scap, the mammalian cholesterol
sensor, is located not in its transmembrane region but in a
membrane-associated loop that projects into the lumen of
the ER (43). As noted in the Introduction, the binding
of PFO to purified ER membranes and the activation of
Scap by ER cholesterol both occur at a common threshold
concentration of 5 mol % cholesterol. Based on our current
understanding of ALO and PFO, it is tempting to speculate
that Scap may be binding to a pool of ER cholesterol that
exceeds the sequestration capacity of ER phospholipidsBiophysical Journal 108(6) 1459–1469and projects out of the ER bilayer. Despite the involvement
of many proteins, a property of the ER lipid bilayer alone
may be a key regulatory element of cholesterol homeostasis
(2,44). Future studies with purified or reconstituted ER
membranes and the tools developed here promise to clarify
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